再组合的H77C gpE1/gpE2异构体产生了比单独的H77C gpE2更好的HCV交叉中和

Juthika Kundu1, Hoa T Le1, Michael Logan1

  • 1Li Ka Shing Applied Virology Institute, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.

Journal of hepatology
|July 10, 2024
PubMed
概括

再组合包膜糖蛋白异构体gpE1/gpE2产生比单独gpE2更广泛的交叉中和抗体,支持将其纳入最佳的型肝炎病毒 (HCV) 疫苗,以获得全球有效性.